Gerresheimer AG (SWX:GXI)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 930.44M -40.8% |
| Revenue (ttm) | 2.16B +16.6% |
| Net Income | -298.56M |
| EPS | -8.64 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.57 |
| Dividend | 0.04 (0.14%) |
| Ex-Dividend Date | Jun 6, 2025 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 26.40 |
| Day's Range | n/a |
| 52-Week Range | 16.16 - 75.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 14, 2026 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality manag... [Read more]
News
Gerresheimer Q4 Earnings Call Highlights
Gerresheimer ETR: GXI said it has completed a broad review of compliance and accounting matters, published its audited 2025 annual report and is now focused on selling Centor, refinancing debt and imp...
Gerresheimer AG Earnings Call Transcript: Q4 2025
Restated and audited 2025 financials reflect extensive compliance work, with revenue at EUR 2.3 billion and flat organic growth. Margin improvement and cash generation are key 2026 priorities, supported by the GTO transformation and planned Centor sale and refinancing.
Gerresheimer AG Annual report: Q4 2025
Gerresheimer AG has published its Q4 2025 annual report on June 29, 2026.
Gerresheimer AG Annual report: Q4 2025
Gerresheimer AG has published its Q4 2025 annual report on June 29, 2026.
Gerresheimer AG Slides: Q4 2025
Gerresheimer AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on June 29, 2026.
Gerresheimer rejects takeover bid from US packing firm Silgan, say sources
German medical packaging maker Gerresheimer has rejected a takeover bid from its U.S. rival Silgan , three sources familiar with the situation told Reuters.
Gerresheimer delays 2025 results release to June, stock to be removed from SDAX
Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker ...
Gerresheimer AG Slides: Investor Presentation
Gerresheimer AG has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2025.
Gerresheimer appoints Uwe Röhrhoff as new interim CEO
Medical equipment maker Gerresheimer said on Tuesday it had appointed Uwe Röhrhoff as interim CEO, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO by mutual agreeme...
Gerresheimer finds 2024 revenue-recognition issues after external probe
Medical equipment maker Gerresheimer said it has obtained the initial findings from an investigation by an external law firm into the recognition of revenue and profit from bill-and-hold agreements in...
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and nine-month results were below expectations, with organic revenue and EBITDA declines driven by weak cosmetics and oral liquids markets. Guidance was revised downward, a transformation program was launched, and liquidity remains strong with no covenant breaches.
Gerresheimer AG Quarterly report: Q3 2025
Gerresheimer AG has published its Q3 2025 quarterly earnings report on October 10, 2025.
Gerresheimer AG Slides: Q3 2025
Gerresheimer AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 10, 2025.
Gerresheimer's shares fall 11% after another outlook cut
Shares in Gerresheimer fell 11% on Thursday, a day after the German packaging and medical equipment maker cut its 2025 guidance for the third time this year.
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and the first nine months of 2025 were below expectations, with organic revenue and EBITDA both declining year-over-year. Guidance was revised downward, with a projected organic revenue decline of -4% to -2% and an adjusted EBITDA margin of 18.5%-19%.
Gerresheimer AG Earnings release: Q3 2025
Gerresheimer AG released its Q3 2025 earnings on October 9, 2025, summarizing the period's financial results.
Gerresheimer AG Slides: Q3 2025
Gerresheimer AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 9, 2025.
Gerresheimer cuts 2025 outlook again as Q3 disappoints
German packaging and medical equipment maker Gerresheimer cut its 2025 guidance again on Wednesday, now expecting organic revenues to decline between 2-4% as third quarter results fell below expectati...
Gerresheimer shares tank as financial regulator suspects accounting flaws
Shares in medical equipment maker Gerresheimer plunged as much as 38% on Wednesday after Germany's financial regulator said it was investigating suspected accounting rule violations.
Gerresheimer CFO resigns unexpectedly, successor to take over from September
Gerresheimer Chief Financial Officer Bernd Metzner has resigned from his role and will leave the company on August 31, the German packaging and medical equipment maker said on Friday.
Activist investor wants review at Gerresheimer after taking stake
Active Ownership, a major shareholder in Gerresheimer , said on Thursday it saw major potential for value creation at the German packaging and medical equipment specialist and called for a strategic r...
Gerresheimer shares rise on plan to sell moulded glass business
Shares of German packaging and medical equipment maker Gerresheimer jumped around 4% in early trading on Tuesday after the company announced plans to sell its moulded glass business late on Monday.
Gerresheimer AG Transcript: Investor Update
Net debt to EBITDA and free cash flow trends were discussed, with expectations for stabilization. Operational focus includes drug delivery systems, plastics, and primary packaging glass, alongside ongoing partnerships and governance initiatives.
Gerresheimer calls a halt to discussions on potential takeover
German packaging and medical equipment maker Gerresheimer has ended discussions on a potential sale of the company, it said on Wednesday evening.
Gerresheimer AG Earnings Call Transcript: Q2 2025
Q2 2025 saw strong reported growth from the Bormioli Pharma acquisition, but organic growth was modest due to ongoing weakness in cosmetics and oral liquids. Guidance for 2025 was lowered, with a focus on margin, cash flow, and deleveraging, while high-value solutions and biologics remain key growth drivers.